Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 38

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 38
---
 use. The Phase 2
Tailwind study represents the second successful clinical trial for AP-PA02, Armata’s lead pulmonary
candidate, which was first evaluated in people with cystic fibrosis in the Phase 1b/2a SWARM-P.a.trial that
completed in 2023. We believe the learnings on dose-schedule regimens gained from the two completed Phase 2 studies position us to
define a safe and promising biologic correlation for a Phase 3 definitive trial to evaluate inhaled AP-PA02 as an alternative to
antibiotics in chronic pulmonary P. aeruginosainfection.

Contingent upon securing
sufficient additional funding, we may at the appropriate time in the future resume clinical development of AP-PA02 for NCFB, which may
include the execution of a definitive Phase 3 clinical trial. We are also actively exploring potential strategic partnerships as a means
to further advance this important program.

<div align='center'>3</div>

Additional Clinical Indications for AP-PA02

The
current Pseudomonas phage cocktail formulated for inhalation (AP-PA02) is prepared with the same high potency and purity of our
injectable phage cocktail for Staphylococcus aureus (“S. aureus”) (AP-SA02). Based on the AP-SA02 clinical
findings, we are exploring the potential development of our Pseudomonas phage cocktail for acute ventilator-associated pneumonia
and severe infections due to multidrug-resistant P. aeruginosa.

Staphylococcus aureusPhage Product Candidate, AP-SA02

Clinical Development of AP-SA02 in Bacteremia: Completed Phase 1b/2a Study

In parallel to developing
novel phage therapeutics that target chronic bacterial infections, we have an acute bacterial infection clinical development plan focused
on S. aureusbacteremia, a difficult-to-treat and often life-threatening human infection that can result in high morbidity and
mortality and for which bacterial resistance to antibiotics is growing.

A key advantage of our
phage manufacturing expertise is the purity profiles of our phage products, including AP-SA02, our phage product candidate
for S. aureus; this has enabled us to pursue treatment of complicated S. aureus bacteremia, where
repetitive intravenous dosing is required. On June 15, 2020, we entered into an agreement (the “MTEC Agreement”